NYSE:QGEN

Qiagen (QGEN) Stock Forecast, Price & News

$39.51

-0.10 (-0.25%)

(As of 02:39 PM ET)

Compare

Today's Range: $39.24
▼
$39.85
50-Day Range: $39.13
▼
$47.22
52-Week Range: $38.98
▼
$51.18

Volume: 618,725 shs
Average Volume: 964,255 shs
Market Capitalization: $9.01 billion

P/E Ratio: 26.88
Dividend Yield: N/A
Price Target: $49.50

Qiagen MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 35.0% Upside
$53.15 Price Target
Short Interest: Healthy
1.43% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: 0.60
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 5.31%
From $2.07 to $2.18 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

159th out of 963 stocks

Biological Products, Except Diagnostic Industry

22nd out of 159 stocks

3.3

Analyst's Opinion

Consensus Rating
Qiagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $53.15, Qiagen has a forecasted upside of 35.0% from its current price of $39.38.
Amount of Analyst Coverage
Qiagen has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.43% of the float of Qiagen has been sold short.
Short Interest Ratio / Days to Cover
Qiagen has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Qiagen has recently decreased by 16.06%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Qiagen does not currently pay a dividend.
Dividend Growth
Qiagen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Qiagen has received a 69.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pharmacovigilance services", "Clinical research services", and "Biochemical assay kits" products. See details.
Environmental Sustainability
The Environmental Impact score for Qiagen is -0.83.

3.1

News and Social Media Coverage

News Sentiment
Qiagen has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Qiagen this week, compared to 4 articles on an average week.
Search Interest
1 people have searched for QGEN on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Qiagen to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Qiagen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Qiagen is held by insiders.
Percentage Held by Institutions
57.99% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Qiagen are expected to grow by 5.31% in the coming year, from $2.07 to $2.18 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Qiagen is 26.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 115.53.
Price to Earnings Ratio vs. Sector
The P/E ratio of Qiagen is 26.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.46.
Price to Earnings Growth Ratio
Qiagen has a PEG Ratio of 9.47. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Qiagen has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Qiagen (NYSE:QGEN) Stock

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

QGEN Price History

30 days | 90 days | 365 days | Advanced Chart

QGEN Stock News Headlines

September 27, 2023 | msn.com

Citigroup Reiterates Qiagen (QGEN) Buy Recommendation

September 27, 2023 | americanbankingnews.com

Qiagen's (QGEN) "Buy" Rating Reaffirmed at Citigroup

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 27, 2023 | americanbankingnews.com

Qiagen (NYSE:QGEN) Receives $49.50 Average Target Price from Brokerages

September 26, 2023 | finance.yahoo.com

QIAGEN (QGEN) Extends QIAwave Product Line With New Kit

September 26, 2023 | finanznachrichten.de

QIAGEN N.V.: QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits

September 26, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Coherus Biosciences (CHRS), Qiagen (QGEN)

September 25, 2023 | finance.yahoo.com

QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 25, 2023 | americanbankingnews.com

Qiagen (NYSE:QGEN) Receives $49.50 Consensus Price Target from Analysts

September 20, 2023 | americanbankingnews.com

Comparing Qiagen (NYSE:QGEN) & Finch Therapeutics Group (NASDAQ:FNCH)

September 13, 2023 | msn.com

Baird Initiates Coverage of Qiagen (QGEN) with Outperform Recommendation

September 12, 2023 | finance.yahoo.com

QIAGEN's (QGEN) New API Streamlines Access to BKB Data

September 9, 2023 | msn.com

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

September 4, 2023 | finance.yahoo.com

Qiagen N.V. (NYSE:QGEN) is largely controlled by institutional shareholders who own 82% of the company

August 22, 2023 | markets.businessinsider.com

Berenberg Bank Reaffirms Their Buy Rating on Qiagen (QGEN)

August 18, 2023 | markets.businessinsider.com

Qiagen (QGEN) Receives a Buy from Citi

August 18, 2023 | markets.businessinsider.com

DZ BANK AG Sticks to Their Buy Rating for Qiagen (QGEN)

August 18, 2023 | markets.businessinsider.com

Qiagen (QGEN) was downgraded to a Hold Rating at Berenberg Bank

August 11, 2023 | markets.businessinsider.com

Kepler Capital Reaffirms Their Hold Rating on Qiagen (QGEN)

August 9, 2023 | seekingalpha.com

Qiagen N.V. 2023 Q2 - Results - Earnings Call Presentation

August 9, 2023 | markets.businessinsider.com

Jefferies Keeps Their Hold Rating on Qiagen (QGEN)

August 8, 2023 | finance.yahoo.com

Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates

August 8, 2023 | markets.businessinsider.com

QIAGEN Reports Q2 Results

August 8, 2023 | finance.yahoo.com

QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook

August 8, 2023 | finance.yahoo.com

QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test

August 8, 2023 | finance.yahoo.com

QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors

See More Headlines

Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Company Calendar

Last Earnings: 8/08/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:QGEN
CUSIP: N/A
CIK: 1015820
Web: www.qiagen.com
Phone: (177) 355-6600
Fax: 31-77-355-6658
Employees: 6,178
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $49.50
High Stock Price Forecast: $60.00
Low Stock Price Forecast: $40.00
Forecasted Upside/Downside: +25.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.47
Trailing P/E Ratio: 26.78
Forward P/E Ratio: 19.02
P/E Growth: 9.47
Net Income: $423.21 million
Net Margins: 17.04%
Pretax Margin: 20.86%
Return on Equity: 13.72%
Return on Assets: 7.54%

Debt

Debt-to-Equity Ratio: 0.38
Current Ratio: 2.36
Quick Ratio: 1.96

Sales & Book Value

Annual Sales: $2.14 billion
Price / Sales: 4.19
Cash Flow: $3.49 per share
Price / Cash Flow: 11.28
Book Value: $15.22 per share
Price / Book: 2.59

Miscellaneous

Outstanding Shares: 228,000,000
Free Float: 207,480,000
Market Cap: $8.98 billion
Optionable: Optionable
Beta: 0.37

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Thierry Bernard (Age 58)
CEO, MD & Member of Management Board
Comp: $2.67M

Dr. Roland Sackers (Age 54)
CFO, MD & Member of Management Board
Comp: $1.33M

Mr. Antonio Santos
Sr. VP & Head of Global Operations

Mr. John Gilardi
VP of Corp. Communications & Investor Relations

Ms. Stephany Foster (Age 44)
Sr. VP & Head of HR

Dr. Thomas Schweins
Sr. VP of Life Science Bus. Area

Dr. Thomas Theuringer
Sr. Director & Head of External Communications

Mr. Jean-Pascal Viola
Sr. VP & Head of Molecular Diagnostics Bus. Area

Dr. Jonathan G. Sheldon Ph.D. (Age 51)
Sr. VP of Qiagen Digital Insights Bus. Area

Mr. Thomas Neidert
VP of Global Treasury

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

QGEN Stock - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QGEN shares.
View QGEN analyst ratings or view top-rated stocks.
What is Qiagen's stock price forecast for 2023?: 6 Wall Street research analysts have issued 12 month target prices for Qiagen's shares. Their QGEN share price forecasts range from $40.00 to $60.00. On average, they anticipate the company's stock price to reach $49.50 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price.
View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts.
How have QGEN shares performed in 2023?: Qiagen's stock was trading at $49.87 at the beginning of 2023. Since then, QGEN shares have decreased by 21.1% and is now trading at $39.37.
View the best growth stocks for 2023 here.
Are investors shorting Qiagen?: Qiagen saw a decrease in short interest in September. As of September 15th, there was short interest totaling 3,240,000 shares, a decrease of 16.1% from the August 31st total of 3,860,000 shares. Based on an average trading volume of 1,250,000 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.4% of the company's shares are sold short.
View Qiagen's Short Interest.
When is Qiagen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our QGEN earnings forecast.
How were Qiagen's earnings last quarter?: Qiagen (NYSE:QGEN) posted its earnings results on Tuesday, August, 8th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.50 by $0.01. The firm had revenue of $497 million for the quarter, compared to analysts' expectations of $492.21 million. Qiagen had a trailing twelve-month return on equity of 13.72% and a net margin of 17.04%. Qiagen's revenue for the quarter was down 8.6% on a year-over-year basis. During the same period last year, the company posted $0.51 earnings per share.
What ETFs hold Qiagen's stock?: ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Newday Ocean Health ETF (AHOY), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).
What guidance has Qiagen issued on next quarter's earnings?: Qiagen updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $2.07- for the period, compared to the consensus estimate of $2.11. The company issued revenue guidance of $1.97B-, compared to the consensus revenue estimate of $2.05 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?: 33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.
What other stocks do shareholders of Qiagen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).
What is Qiagen's stock symbol?: Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."
Who are Qiagen's major shareholders?: Qiagen's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.31%), DekaBank Deutsche Girozentrale (1.45%), Perpetual Ltd (1.17%), Marshall Wace LLP (1.17%), State Street Corp (0.97%) and Barclays PLC (0.72%).
How do I buy shares of Qiagen?: Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Qiagen's stock price today?: One share of QGEN stock can currently be purchased for approximately $39.37.
How much money does Qiagen make?: Qiagen (NYSE:QGEN) has a market capitalization of $8.98 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.47 on an earnings per share basis.
How many employees does Qiagen have?: The company employs 6,178 workers across the globe.
How can I contact Qiagen?: Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.

This page (NYSE:QGEN) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Qiagen (QGEN) Stock Forecast, Price & News

Qiagen MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Qiagen (NYSE:QGEN) Stock

QGEN Price History

QGEN Stock News Headlines

QGEN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

QGEN Stock - Frequently Asked Questions

Overall MarketRank^™